| Stereochemistry | ACHIRAL |
| Molecular Formula | 2Cl.Ra |
| Molecular Weight | 293.924 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].[223Ra++]
InChI
InChIKey=RWRDJVNMSZYMDV-SIUYXFDKSA-L
InChI=1S/2ClH.Ra/h2*1H;/q;;+2/p-2/i;;1-3
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
MOL RATIO
2 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Ra |
| Molecular Weight | 223.0185 |
| Charge | 2 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Radium Ra 223 dichloride is a radiotherapeutic drug that is approved for the treatment of male patients with symptoms of advanced prostate cancer with bone metastases. Ra 223 mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover. The radioactive alpha particles emitted by radium Ra 223 helps in killing cancer cells in the bone by damaging their DNA. Radium Ra 223 causes minimal damage to the nearby healthy cells.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
The dose regimen is 50 kBq (1.35 microcurie) per kg body weight, given at 4 week intervals for 6 injections.
Route of Administration:
Intravenous
